OMTH
Omthera PharmaceuticalsNASDAQ
OMTH is defunct.
  • May 28, 2013, 8:11 AM

    Omthera (OMTH) rockets 99% to $13.50 following news that AstraZeneca (AZN) has agreed to acquire the heart-drug company for up to $443M. The upfront payment of $323M is worth $12.70 a share, while a secondary contingent payment of $120M is worth $4.70. AstraZeneca is +2.4%.

    | May 28, 2013, 8:11 AM
  • May 28, 2013, 2:48 AM

    AstraZeneca (AZN) has agreed to acquire Omthera Pharmaceuticals (OMTH) for up to $443M as the U.K. company carries out its strategy of building up its cardiovascular drug business. The price includes an upfront payment of $323M, or $12.70 a share, which represents an 88% premium to Omthera's close on Friday. AstraZeneca will pay another $120M based on the success of Omthera's experimental drug Epanova for treating very high levels of triglycerides, a fat found in the blood. (PR)

    | May 28, 2013, 2:48 AM